Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1904
Shown on this page
12
Current sort
Recently updated
Sponsor scope
AstraZeneca
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within AstraZeneca. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 793–804 of 1,904 matching trials for sponsor AstraZeneca.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Results available

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

NCT02718911
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3022855, Durvalumab, Tremelimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Sarasota, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Recruiting Not applicable Interventional

PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.

NCT05306743
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CONQUEST Quality Improvement Program
Other
Lead sponsor
Observational and Pragmatic Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Denver, Colorado • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Terminated Phase 2 Interventional Results available

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

NCT03490760
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Durvalumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 2 Interventional Results available

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

NCT02904954
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Durvalumab plus SBRT
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT02125461
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736, PLACEBO
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 3 Interventional Results available

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

NCT02987543
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
olaparib, enzalutamide, abiraterone acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Terminated Phase 3 Interventional Results available

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

NCT04727528
View directory record Official record
Conditions
Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Florence, Alabama • Chula Vista, California • Downey, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 2 Interventional Results available

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02272790
View directory record Official record
Conditions
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions
Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
18
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

NCT04212169
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MEDI3506, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 2 Interventional Results available

Preventing Anaphylaxis With Acalabrutinib

NCT05038904
View directory record Official record
Conditions
Food Allergy, Food Allergy Peanut
Interventions
Acalabrutinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed No phase listed Observational

Long-term Observational Study of the Safety of Roflumilast

NCT03381573
View directory record Official record
Conditions
COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
135,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 5, 2026, 10:31 AM EST
Completed Phase 2 Interventional Results available

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

NCT02639065
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Durvalumab
Drug
Lead sponsor
Shadia Jalal, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Nov 5, 2026, 10:31 AM EST

About this AstraZeneca sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for AstraZeneca.